A prospective evaluation of the predictive value of faecal calprotectin in quiescent Crohn's disease

Journal of Crohn's and Colitis

Volumn 8, Issue 9, 2014, Pages 1022-1029

  Naismith, Graham D ^a   Smith, Lyn A ^a   Barry, Sarah J E ^b   Munro, Joanna I ^a   Laird, Susan ^a   Rankin, Karen ^a   Morris, Allan J ^a   Winter, Jack W ^a   Gaya, Daniel R ^a  

^a GLASGOW ROYAL INFIRMARY   (United Kingdom)

^b UNIVERSITY OF GLASGOW   (United Kingdom)

Author keywords

Crohn's disease; ; Disease activity measurements; ; Inflammation in IBD

Indexed keywords

CALGRANULIN;

ADULT; ARTICLE; CROHN DISEASE; DIAGNOSTIC TEST ACCURACY STUDY; FECES LEVEL; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; PREDICTIVE VALUE; PRIORITY JOURNAL; PROSPECTIVE STUDY; RELAPSE; REMISSION; SENSITIVITY AND SPECIFICITY; BIOCHEMICAL ANALYSIS; ENZYME LINKED IMMUNOSORBENT ASSAY; FECES ANALYSIS; MIDDLE AGED; RECURRENCE RISK; RISK ASSESSMENT; ADOLESCENT; AGED; CHEMISTRY; FECES; METABOLISM; PROGNOSIS; RECEIVER OPERATING CHARACTERISTIC; REPRODUCIBILITY; SEVERITY OF ILLNESS INDEX; TIME; VERY ELDERLY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CROHN DISEASE; FECES; FEMALE; FOLLOW-UP STUDIES; HUMANS; LEUKOCYTE L1 ANTIGEN COMPLEX; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PROSPECTIVE STUDIES; REPRODUCIBILITY OF RESULTS; ROC CURVE; SEVERITY OF ILLNESS INDEX; TIME FACTORS; YOUNG ADULT;

EID: 84906791104     PISSN: 18739946     EISSN: 18764479     Source Type: Journal    
DOI: 10.1016/j.crohns.2014.01.029     Document Type: Article

References (42)

1. Roseth A.G., Schmidt P.N., Fagerhol M.K. Correlation between faecal excretion of indium-111-labelled granulocytes and calprotectin, a granulocyte marker protein in patients with inflammatory bowel disease. Scand J Gastroenterol 1999, 34(1):50-54.
2. Roseth A.G., Aadland E., Jahnsen J., Raknerud N. Assessment of disease activity in ulcerative colitis by faecal calprotectin, a novel granulocyte marker protein. Digestion 1997, 58(2):176-180.
3. Sipponen T., Savilahti E., Kolho K.L., Nuutinen H., Turunen U., Farkkila M. Crohn's disease activity assessed by fecal calprotectin and lactoferrin: correlation with Crohn's disease activity index and endoscopic findings. Inflamm Bowel Dis 2008, 14(1):40-46.
4. Tibble J., Teahon K., Thjodleifsson B., Roseth A., Sigthorsson G., Bridger S., et al. A simple method for assessing intestinal inflammation in Crohn's disease. Gut 2000, 47(4):506-513.
5. Sutherland A.D., Geary R.B., Frizelle F.A. Review of fecal biomarkers in inflammatory bowel disease. Dis Colon Rectum 2008, 51(8):1283-1291.
6. Schoepfer A.M., Trummler M., Seeholzer P., Seibold-Schmid B., Seibold F. Discriminating IBD from IBS: comparison of the test performance of fecal markers, blood leucocytes, CRP and IBD antibodies. Inflamm Bowel Dis 2008, 14(1):32-39.
7. Gisbert J.P., McNicholl A.G. Questions and answers on the role of faecal calprotectin as a biological marker in inflammatory bowel disease. Dig Liver Dis 2009, 41(1):55-66.
8. Centre for Evidence-based purchasing. Value of calprotectin in screening out irritable bowel syndrome: evidence review 2009, CEP09026. NHS Purchasing and Supply Agency, London.
9. Roseth A.G., Aadland E., Grzyb K. Normalization of faecal calprotectin: a predictor of mucosal healing in patients with inflammatory bowel disease. Scand J Gastroenterol 2004, 39(10):1017-1020.
10. Langhorst J., Elsenbruch S., Koelzer J., Rueffer A., Michalsen A., Dobos G.J. Noninvasive markers in the assessment of intestinal inflammation in inflammatory bowel disease: performance of fecal lactoferrin, calprotectin and PMN-elastase, CRP and clinical indices. Am J Gastroenterol 2008, 103(1):162-169.
11. Jones J., Loftus E.V., Panaccione R., Chen L.S., Peterson S., McConnell J., et al. Relationships between disease activity and serum and fecal biomarkers in patients with Crohn's disease. Clin Gastroenterol Hepatol 2008, 6(11):1218-1224.
12. Schoepfer A.M., Beglinger C., Straumann A., Trummler M., Vavricka S.R., Bruegger L.E., et al. Fecal calprotectin correlates more closely with the Simple Endoscopic Score for Crohn's disease (SES-CD) than CRP, leukocytes and the CDAI. Am J Gastroenterol 2009, 105(1):162-169.
13. Tibble J.A., Sigthorsson G., Bridger S., Fagerhol M.K., Bjarnason I. Surrogate markers of intestinal inflammation are predictive of relapse in patients with inflammatory bowel disease. Gastroenterology 2000, 119(1):15-22.
14. Costa F., Mumolo M.G., Ceccarelli L., Bellini M., Romano M.R., Sterpi C., et al. Calprotectin is a stronger predictive marker of relapse in ulcerative colitis than in Crohn's disease. Gut 2005, 54(3):364-368.
15. D'Incà R., Dal Pont E., Di Leo V., Benazzato L., Martinato M., Lamboglia F., et al. Can calprotectin predict relapse risk in inflammatory bowel disease?. Am J Gastroenterol 2008, 103(8):2007-2014.
16. Gisbert J.P., Bermejo F., Pérez-Calle J.L., Taxonera C., Vera I., McNicholl A.G., et al. Fecal calprotectin and lactoferrin for the prediction of inflammatory bowel disease relapse. Inflamm Bowel Dis 2009, 15(8):1190-1198.
17. García-Sánchez V., Iglesias-Flores E., González R., Gisbert J.P., Gallardo-Valverde J.M., González-Galilea A., et al. Does fecal calprotectin predict relapse in patients with Crohn's disease and ulcerative colitis?. J Crohns Colitis 2010, 4(2):144-152.
18. Kallel L., Ayadi I., Matri S., Fekih M., Mahmoud N.B., Feki M., et al. Fecal calprotectin is a predictive marker of relapse in Crohn's disease involving the colon: a prospective study. Eur J Gastroenterol Hepatol 2010, 22(3):340-345.
19. Laharie D., Mesli S., El Hajbi F., Chabrun E., Chanteloup E., Capdepont M., et al. Prediction of Crohn's disease relapse with faecal calprotectin in infliximab responders: a prospective study. Aliment Pharmacol Ther 2011, 34(4):462-469.
20. Mao R., Xiao Y.L., Gao X., Chen B.L., He Y., Yang L., et al. Fecal calprotectin in predicting relapse of inflammatory bowel diseases: a meta-analysis of prospective studies. Inflamm Bowel Dis 2012, 18(10):1894-1899.
21. Best W.R., Becktel J.M., Singleton J.W., Kern F. Development of a Crohn's disease activity index. National Cooperative Crohn's Disease Study. Gastroenterology 1976, 70(3):439-444.
22. Naismith G.D., Smith L.A., Barry S.J.E., Munro J.I., Laird S., Rankin K., et al. A prospective single centre evaluation of the intra-individual variability of the faecal calprotectin test in quiescent Crohn's disease. Aliment Pharmacol Ther 2013, 37(6):613-621.
23. Manz M., Burri E., Rothen C., Tchanguizi N., Niederberger C., Rossi L., et al. Value of fecal calprotectin in the evaluation of patients with abdominal discomfort: an observational study. BMC Gastroenterol 2012, 12(1):5.
24. Van Rheenen P.F., Van de Vijver E., Fidler V. Faecal calprotectin for screening of patients with suspected inflammatory bowel disease: diagnostic meta-analysis. BMJ 2010, 341:c3369.
25. Wagner M., Peterson C.G., Ridefelt P., Sangfelt P., Carlson M. Fecal markers of inflammation used as surrogate markers for treatment outcome in relapsing inflammatory bowel disease. World J Gastroenterol 2008, 14(36):5584-5589.
26. Sipponen C.J., Af Björkesten M., Farkkila H., Nuutinen E., Savilahti, Kolho K-L. Faecal calprotectin and lactoferrin are reliable surrogate markers of endoscopic response during Crohn's disease treatment. Scand J Gasterenterol 2010, 45(3):325-331.
27. Lamb C.A., Mohiuddin M.K., Gicquel J., Neely D., Bergin F.G., Hanson J.M., et al. Faecal calprotectin or lactoferrin can identify postoperative recurrence in Crohn's disease. Br J Surg 2009, 96(6):663-674.
28. Boschetti G., Moussata D., Charlois A.L., Flourié B., Nancey S. P314. Accuracy of fecal calprotectin in the assessment of post-operative endoscopic recurrence in patients with Crohn's disease. J Crohns Colitis 2013, 7:S134-S135.
29. Beltrán B., Cerrillo E., Iborra M., Moret I., Rausell F., Tortosa L., et al. P172. Fecal calprotectin (FC) is a useful early predictive marker for postoperative recurrence in Crohn's disease (CD). J Crohns Colitis 2012, 6:S78.
30. Guidi L., Marzo M., Andrisani G., Felice C., Pugliese D., DeVitis I., et al. P214. Faecal calprotectin assay after induction with anti-TNF alpha agents in IBD patients: prediction of clinical response and mucosal healing at one year. J Crohns Colitis 2013, 7:S95.
31. Ferreiro R., Barreiro-de Acosta M., Otero M., Lorenzo A., Alonso C., Dominguez-Munoz J.E. P109. Use of faecal calprotectin as predictor of relapse in patients under maintenance treatment with infliximab. J Crohns Colitis 2013, 7:S52-S53.
32. Molander P., Af Björkesten C.G., Mustonen H., Haapamäki J., Vauhkonen M., Kolho K.L., et al. Fecal calprotectin concentration predicts outcome in inflammatory bowel disease after induction therapy with TNFα blocking agents. Inflamm Bowel Dis 2012, 18(11):2011-2017.
33. D'Haens G., Ferrante M., Vermeire S., Baert F., Noman M., Moortgat L., et al. Fecal calprotectin is a surrogate marker for endoscopic lesions in inflammatory bowel disease. Inflamm Bowel Dis 2012, 18(12):2218-2224.
34. Hanaway P., Roseth A. Inflammatory biomarkers predict relapse in IBD. Gut 2005, 54(9):1346-1347.
35. Pardi D.S., Sandborn W.J. Predicting relapse in patients with inflammatory bowel disease: what is the role of biomarkers?. Gut 2005, 54(3):321-322.
36. Lemann M., Mary J.Y. Calprotectin and IBD. Gut 2005, 54(9):1349-1350.
37. Saverymuttu S.H., Peters A.M., Crofton M.E., Rees H., Lavender J.P., Hodgson H.J., et al. 111 Indium autologous granulocytes in the detection of inflammatory bowel disease. Gut 1985, 26(9):955-960.
38. Primas C., Frühwald G., Angelberger S., Allerstorfer D., Papay P., Eser A., et al. P381. Role of fecal calprotectin in predicting ileocolonic endoscopic recurrence in postoperative Crohn's disease. J Crohns Colitis 2013, 7:S162.
39. Kennedy N.A., Chang J., Guy M.H., Smith T., Loh J.T., Haunschmidt D., et al. P250. Elevated faecal calprotectin predicts disease progression in Crohn's disease. J Crohns Colitis 2013, 7:S109-S110.
40. Louis E., Mary J.Y., Vernier-Massouille G., Grimaud J.C., Bouhnik Y., Laharie D., et al. Maintenance of remission among patients with Crohn's disease on antimetabolite therapy after infliximab therapy is stopped. Gastroenterology 2012, 142(1):63-70.
41. De Suray N., Salleron J., Vernier-Massouille G., Grimaud J.C., Bouhnik Y., Laharie D., et al. 864 Close monitoring of CRP and fecal calprotectin is able to predict clinical relapse in patients with Crohn's Disease in remission after infliximab withdrawal. A sub-analysis of the Stori study. Gastroenterology 2012, 142(5):S-149.
42. Cosnes J., Cattan S., Blain A., Beaugerie L., Carbonnel F., Parc R., et al. Long-term evolution of disease behavior of Crohn's disease. Inflamm Bowel Dis 2002, 8(4):244-250.